Short answer
PROCEPT BioRobotics Corp (PRCT) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $83M (up 42.8% year over year) with net income of −$21M.
Q3 2025 key financials · XBRL
- Revenue
- $83M
- +42.8% YoY · +5.2% QoQ
- Net income
- −$21M
- −2.1% YoY · −9.4% QoQ
- Operating margin
- -27.8%
- Gross margin
- 64.8%
- EPS (diluted)
- −$0.39
- +2.5% YoY · −11.4% QoQ
Source: XBRL data from the PROCEPT BioRobotics Corp (PRCT) Q3 2025 10-Q on SEC EDGAR. USD.
PROCEPT BioRobotics Corp Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new risk factors added this quarter, per explicit statement of no material changes
- Regulatory risk unchanged, includes FDA clearance challenges discussed in 2024 10-K with ongoing clinical trial scrutiny
- Market risk from competitive medical robotics advances continues impacting near-term sales growth potential
- Financial risk from liquidity remains linked to cash burn rate and timing of anticipated product revenue ramp
- Legal risk from intellectual property disputes persists as a key contingent matter affecting operational stability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PROCEPT BioRobotics Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.